TaiGen begins Phase I/II trial of burixafor in China to treat acute myeloid leukemia
Burixafor (TG-0054) is a new, potent and selective chemokine receptor antagonist discovered by TaiGen. Around 15 patients will be enrolled in this open-label trial, which is designed to